RITALIN LA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for RITALIN LA (RITALIN LA).

How it works

Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.

What the body does with it

Metabolism	Primarily hepatic via deesterification to ritalinic acid (inactive). CYP2D6 plays a minor role.
Excretion	Renal (78–97% as metabolites, primarily ritalinic acid, with <1% unchanged); fecal <2%
Half-life	Methylphenidate: 3–4 hours (racemic); d-enantiomer: 6–8 hours; clinical context: duration of action 8–12 hours due to extended-release formulation
Protein binding	10–15% (primarily to albumin)
Volume of Distribution	2.65 L/kg (likely higher due to extensive tissue distribution; reflects wide distribution into brain and other tissues)
Bioavailability	Oral: 22–25% (racemic); d-enantiomer higher due to stereoselective first-pass metabolism
Onset of Action	Oral (LA capsule): 1–2 hours (initial peak); biphasic release with second peak at 4–5 hours
Duration of Action	8–12 hours; clinical note: designed for once-daily dosing with less rebound than immediate-release

Classification & Brands

Dosing & administration

20-60 mg orally once daily in the morning; capsules may be swallowed whole or sprinkled on applesauce.

Dosage form	CAPSULE, EXTENDED RELEASE
Renal impairment	No specific dose adjustment recommended; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for increased exposure.
Liver impairment	Child-Pugh Class A: no adjustment. Class B or C: reduce dose by 50% or use alternative.
Pediatric use	Children 6-12 years: 20-40 mg orally once daily in the morning; maximum 60 mg/day. Adolescents: same as adult dosing.
Geriatric use	Initiate at lowest effective dose (20 mg/day); monitor for hypertension, tachycardia, and appetite suppression. Consider alternative if comorbid conditions present.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for RITALIN LA (RITALIN LA).

Breastfeeding	Methylphenidate is excreted into breast milk; estimated infant dose is 0.2-0.7% of maternal weight-adjusted dose. M/P ratio is not well-established. Monitor infant for agitation, insomnia, and poor weight gain. Consider alternative if possible.
Teratogenic Risk	First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second/third trimester: Possible increased risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms (e.g., irritability, dysphoria) with chronic use. Avoid unless benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

RITALIN LA has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to methylphenidate or any component of the formulation","Concurrent treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIs","Glaucoma","Tics or Tourette's syndrome (or family history)","Severe hypertension, angina pectoris, cardiac arrhythmias, or other structural cardiac abnormalities","Hyperthyroidism","Agitated states","Drug abuse or alcoholism"]

Clinical Precautions

Precautions

["Serious cardiovascular events: Sudden death in patients with structural cardiac abnormalities or other serious heart problems.","Psychiatric adverse events: Exacerbation of pre-existing psychosis, mania, or aggression.","Seizures: Use with caution in patients with history of seizures.","Growth suppression: Monitor growth during treatment.","Hematologic effects: Monitor for leukopenia, anemia, thrombocytopenia.","Peripheral vasculopathy: Raynaud's phenomenon.","Long-term suppression of growth.","Visual disturbances: Blurred vision."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

RITALIN LA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for RITALIN LA (RITALIN LA).

How it works

Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.

What the body does with it

Metabolism	Primarily hepatic via deesterification to ritalinic acid (inactive). CYP2D6 plays a minor role.
Excretion	Renal (78–97% as metabolites, primarily ritalinic acid, with <1% unchanged); fecal <2%
Half-life	Methylphenidate: 3–4 hours (racemic); d-enantiomer: 6–8 hours; clinical context: duration of action 8–12 hours due to extended-release formulation
Protein binding	10–15% (primarily to albumin)
Volume of Distribution	2.65 L/kg (likely higher due to extensive tissue distribution; reflects wide distribution into brain and other tissues)
Bioavailability	Oral: 22–25% (racemic); d-enantiomer higher due to stereoselective first-pass metabolism
Onset of Action	Oral (LA capsule): 1–2 hours (initial peak); biphasic release with second peak at 4–5 hours
Duration of Action	8–12 hours; clinical note: designed for once-daily dosing with less rebound than immediate-release

Classification & Brands

Dosing & administration

20-60 mg orally once daily in the morning; capsules may be swallowed whole or sprinkled on applesauce.

Dosage form	CAPSULE, EXTENDED RELEASE
Renal impairment	No specific dose adjustment recommended; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for increased exposure.
Liver impairment	Child-Pugh Class A: no adjustment. Class B or C: reduce dose by 50% or use alternative.
Pediatric use	Children 6-12 years: 20-40 mg orally once daily in the morning; maximum 60 mg/day. Adolescents: same as adult dosing.
Geriatric use	Initiate at lowest effective dose (20 mg/day); monitor for hypertension, tachycardia, and appetite suppression. Consider alternative if comorbid conditions present.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for RITALIN LA (RITALIN LA).

Breastfeeding	Methylphenidate is excreted into breast milk; estimated infant dose is 0.2-0.7% of maternal weight-adjusted dose. M/P ratio is not well-established. Monitor infant for agitation, insomnia, and poor weight gain. Consider alternative if possible.
Teratogenic Risk	First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second/third trimester: Possible increased risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms (e.g., irritability, dysphoria) with chronic use. Avoid unless benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

RITALIN LA has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.